Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ondansetron for hallucinations in Parkinson's disease
ISRCTN51996779Phase 2Recruiting
- Sponsor
- PRIMENT Clinical Trials Unit
- Start
- Apr 2020
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing Ondansetron with Placebo (2 arms). Primary endpoint: Primary: Visual hallucinations. Started Apr 2020; status: recruiting.
02
Drugs
ondansetron
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on ISRCTN51996779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN51996779.